Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
Atherosclerosis has shared a post on LinkedIn:
“Lp(a) Testing: A Cost-Saving Tool for Cardiovascular Prevention
High Lp(a) levels are a known cardiovascular risk factor, but is testing for Lp(a) worth it from a healthcare perspective?
A recent microsimulation study modeled 10,000 adults aged 40–69 without prior CVD from the UK Biobank. The study evaluated Lp(a) testing in individuals not initially high-risk. Those with Lp(a) ≥105 nmol/L were reclassified as high-risk and received statins and blood pressure–lowering therapy.
Key findings:
- Out of 10,000 individuals, 1,807 had their treatment modified based on Lp(a).
- 217–255 quality-adjusted life years gained in Australia and the UK.
- Cost-effectiveness ratios: $12,134 AUD (cost-effective) and −£3,491 GBP (cost-saving).
- From a societal perspective, testing saved $85 AUD and £263 GBP per person.
- Modeling across multiple countries showed Lp(a) testing to be cost-saving everywhere.
Takeaway: Lp(a) testing in primary prevention reclassifies risk, guides therapy, and saves costs—supporting its adoption as a preventive strategy against CVD.
This study makes a compelling case for integrating Lp(a) measurement into routine cardiovascular risk assessment.”
Title: Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Author: Jedidiah I. Morton, Florian Kronenberg, Magdalena Daccord, Nicola Bedlington, Marius Geant, Tobias Silberzahn, Zhenyue Chen, Jean-Luc Eisele, Bogi Eliasen, Mariko Harada-Shiba, Marc Rijken, Albert Wiegman, George Thanassoulis, Pia R. Kamstrup, Iñaki Gutierrez-Ibarluzea, Pablo Coral, Raul D. Santos, Erik Stroes, Michal Vrablik, Gerald F. Watts, Christie M. Ballantyne, Samia Mor, Børge G. Nordestgaard, Kausik K. Ray, Stephen J. Nicholls, Zanfina Ademi
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 14, 2025, 11:17Isabelle Mahé on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results
-
Sep 13, 2025, 13:32Beta Thalassemia Major After Splenectomy: Setareh Sheikhi Reports Striking nRBC Surge Reports Striking nRBC Surge
-
Sep 13, 2025, 13:26Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 14, 2025, 14:36Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
-
Sep 14, 2025, 12:37Ivan Budnik Highlights New Framework for Thrombus Resolution Analysis in Mouse IVC Stenosis Model
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 13:35Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
-
Sep 13, 2025, 13:20Giulia Simini: Our Review on the Hepatic Life Cycle of AAV is Now Available in JTH
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere